Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma | Synapse

December 10, 2025

View Full Paper

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

NJNathalie A. JohnsonOslo University Hospital

Pier Luigi ZinzaniUniversité Claude Bernard Lyon 1 EDEva Domingo‐DoménechDuran i Reynals Hospital

Key Points

Evaluate the efficacy of nivolumab plus brentuximab vedotin in treating relapsed/refractory diffuse large B-cell lymphoma.
Analysis of efficacy data from CheckMate 436 trial
Efficacy data do not support the use of nivolumab plus brentuximab vedotin for R/R DLBCL treatment

Abstract

Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Johnson et al. (Wed,) studied this question.

synapsesocial.com/papers/69401b312d562116f28f7cb2 https://doi.org/https://doi.org/10.1080/14796694.2025.2599082